Free tool
FAERS Monitor: Zynrelef Kit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211988 or its brand name (Zynrelef Kit, Bupivacaine, Meloxicam). Reports on generic versions are filed under their own applications.
Reports
213
Serious
53
25% of reports
Hospitalization
14
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- wound dehiscence30
- suture related complication18
- procedural nausea17
- seroma12
- wound necrosis12
- skin odour abnormal11
- blister10
- pain10
- product odour abnormal10
- nausea9
- no adverse event9
- drug ineffective8
- post procedural drainage8
- rash8
- erythema7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2022 | 91 |
| 2023 | 58 |
| 2024 | 19 |
| 2025 | 24 |
| 2026 | 20 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,946 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| post procedural drainageSignal | 8 | 5772.0 | 2865.9 | 38,331 |
| suture related complicationSignal | 18 | 2582.3 | 1649.4 | 42,784 |
| wound necrosisSignal | 12 | 2529.1 | 1448.9 | 27,155 |
| procedural nauseaSignal | 17 | 2132.4 | 1344.4 | 33,398 |
| seromaSignal | 12 | 941.4 | 541.8 | 10,255 |
| wound dehiscenceSignal | 30 | 884.6 | 633.8 | 25,380 |
| skin odour abnormalSignal | 11 | 276.9 | 155.6 | 2,747 |
| product odour abnormalSignal | 10 | 94.4 | 51.5 | 832 |
| blisterSignal | 10 | 17.6 | 9.6 | 141 |
| no adverse eventSignal | 9 | 4.9 | 2.6 | 24 |
| erythemaSignal | 7 | 3.4 | 1.6 | 9 |
| rash | 8 | 1.8 | 0.9 | 2 |
| pain | 10 | 1.6 | 0.9 | 2 |
| nausea | 9 | 1.1 | 0.6 | 0 |
| drug ineffective | 8 | 0.6 | 0.3 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.